Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Man Group plc

Man Group plc boosted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 746,463 shares of the company's stock after acquiring an additional 27,813 shares during the quarter. Man Group plc owned 0.73% of Dyne Therapeutics worth $17,587,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock worth $5,532,000 after acquiring an additional 698 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares during the period. KBC Group NV grew its stake in Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares in the last quarter. E Fund Management Co. Ltd. grew its stake in Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after purchasing an additional 1,249 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Dyne Therapeutics by 11.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock worth $508,000 after purchasing an additional 2,265 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Performance

DYN stock traded up $0.24 during trading on Thursday, reaching $12.00. The company had a trading volume of 273,454 shares, compared to its average volume of 1,656,666. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -3.36 and a beta of 1.19. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $47.45. The firm has a 50-day simple moving average of $10.35 and a 200-day simple moving average of $17.16.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. BMO Capital Markets began coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price for the company. JPMorgan Chase & Co. decreased their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Chardan Capital reiterated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, May 9th. HC Wainwright cut their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.25.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.